CO2023006818A2 - Degradadores de irak y sus usos - Google Patents

Degradadores de irak y sus usos

Info

Publication number
CO2023006818A2
CO2023006818A2 CONC2023/0006818A CO2023006818A CO2023006818A2 CO 2023006818 A2 CO2023006818 A2 CO 2023006818A2 CO 2023006818 A CO2023006818 A CO 2023006818A CO 2023006818 A2 CO2023006818 A2 CO 2023006818A2
Authority
CO
Colombia
Prior art keywords
degraders
iraq
compositions
methods
present
Prior art date
Application number
CONC2023/0006818A
Other languages
English (en)
Spanish (es)
Inventor
Xiaozhang Zheng
Xiao Zhu
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of CO2023006818A2 publication Critical patent/CO2023006818A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CONC2023/0006818A 2020-12-09 2023-05-25 Degradadores de irak y sus usos CO2023006818A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063123330P 2020-12-09 2020-12-09
PCT/US2021/062640 WO2022125790A1 (en) 2020-12-09 2021-12-09 Irak degraders and uses thereof

Publications (1)

Publication Number Publication Date
CO2023006818A2 true CO2023006818A2 (es) 2023-07-10

Family

ID=81973811

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0006818A CO2023006818A2 (es) 2020-12-09 2023-05-25 Degradadores de irak y sus usos

Country Status (13)

Country Link
US (2) US20230096599A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259128A4 (cg-RX-API-DMAC7.html)
JP (1) JP7832945B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230130179A (cg-RX-API-DMAC7.html)
CN (1) CN116669722A (cg-RX-API-DMAC7.html)
AR (1) AR124294A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021396308A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200608A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006818A2 (cg-RX-API-DMAC7.html)
IL (1) IL303458A (cg-RX-API-DMAC7.html)
MX (1) MX2023006719A (cg-RX-API-DMAC7.html)
TW (1) TW202237601A (cg-RX-API-DMAC7.html)
WO (1) WO2022125790A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
EP4393922A4 (en) * 2021-08-23 2026-01-28 Leadingtac Pharmaceutical Shaoxing Co Ltd IRAK4 DEGRADATION AGENT, ITS PREPARATION PROCESS AND ITS USE
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
WO2024020084A1 (en) * 2022-07-20 2024-01-25 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
KR20260048566A (ko) * 2023-07-13 2026-04-10 인크레랜드 방향족 화합물, 이를 포함하는 약제학적 조성물 및 이의 용도
EP4759807A1 (en) 2023-08-11 2026-06-17 Shenzhen Zhongge Biological Technology Co., Ltd. Proteolysis targeting chimera compound for degrading irak4 and use thereof
EP4775569A1 (en) * 2023-09-08 2026-07-15 The Global Health Drug Discovery Institute 3cl protease inhibitor for treating or preventing coronavirus infections and use thereof
WO2025108406A1 (zh) * 2023-11-22 2025-05-30 广东东阳光药业股份有限公司 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
WO2025168131A1 (zh) * 2024-02-08 2025-08-14 清华大学 一种多靶降解剂及其用途
WO2026136763A1 (en) 2024-12-19 2026-06-25 Bristol-Myers Squibb Company Genetic predictor for il18 driven disease
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201728592A (zh) * 2012-01-10 2017-08-16 林伯士艾瑞斯公司 Irak抑制劑及其用途
HK1254469A1 (zh) * 2015-06-26 2019-07-19 Dana Farber Cancer Institute, Inc. 稠合双环嘧啶衍生物及其用途
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
US11065231B2 (en) * 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US12454520B2 (en) * 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2019389174A1 (en) * 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP7874541B2 (ja) * 2019-09-16 2026-06-16 ノバルティス アーゲー 接着分解剤及びその使用方法
WO2021188948A1 (en) * 2020-03-19 2021-09-23 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof

Also Published As

Publication number Publication date
EP4259128A1 (en) 2023-10-18
IL303458A (en) 2023-08-01
EP4259128A4 (en) 2025-04-30
AU2021396308A9 (en) 2025-03-20
US20230096599A1 (en) 2023-03-30
KR20230130179A (ko) 2023-09-11
AU2021396308A1 (en) 2023-06-22
CA3200608A1 (en) 2022-06-16
JP7832945B2 (ja) 2026-03-18
AR124294A1 (es) 2023-03-15
TW202237601A (zh) 2022-10-01
CN116669722A (zh) 2023-08-29
US20250375526A1 (en) 2025-12-11
WO2022125790A1 (en) 2022-06-16
MX2023006719A (es) 2023-06-23
JP2023552827A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
CO2023008362A2 (es) Degradadores de irak y sus usos
CO2022008406A2 (es) Degradadores de irak y usos de los mismos
CO2021007068A2 (es) Degradadores de irak y usos de los mismos
CO2023014770A2 (es) Degradadores de cdk2 y sus usos
MX2023006719A (es) Degradadores de cinasas asociadas con el receptor de interleucina 1 (irak) y sus usos.
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CO2024011512A2 (es) Degradadores de irak y usos de los mismos referencia a solicitudes relacionadas
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2025009897A2 (es) Degradadores de irak y usos de los mismos
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2022011437A (es) Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
BR112021011124A2 (pt) Anelossomos e métodos de uso
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
CO2024004970A2 (es) Agentes degradantes de tyk2 y sus usos
MX2020009465A (es) Anticuerpos anti-klk5 y metodos de uso.
CO2021000147A2 (es) Composición agrícola
CL2023003151A1 (es) Anticuerpos anti-notch2 y métodos de uso
MX2017010526A (es) Mezclas de aceite, procesos para la preparacion de estas y su uso en formulas.
MX383386B (es) Nuevos inhibidores de braf y uso de los mismos para el tratamiento de reacciones cutáneas.
CO2025016192A2 (es) Moléculas y métodos de uso de estas